The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening
Have Stage 1b or Stage 2 type 1 diabetes
Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening
Have any other type of diabetes
Have uncontrolled high blood pressure
Have had a heart attack, heart disease, stroke, or heart failure
Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
Parallel
Baricitinib
DrugAdministered orally
Placebo
DrugAdministered orally
Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes
Change from Baseline in Glucose-Stimulated C-peptide Area Under the Curve (AUC)
Change from Baseline in Glucose AUC
Change from Baseline in AUC Ratio (AUC C-peptide/AUC Glucose × 1000)
Change from Baseline in Height
Click on the lead sponsor to view all of their trials.
